Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

TTNP RSS Feed
Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rentier, TRUTH
Search This Board:
Last Post: 10/30/2014 10:12:27 AM - Followers: 156 - Board type: Free - Posts Today: 0


 






Products


Probuphine®-This study is enrolling participants by invitation only.

Click For Link To ClinicalTrials.gov


*As of September 23, 2014 -  50% enrolled.


Sponsor:

Braeburn Pharmaceuticals


ClinicalTrials.gov Identifier:
Information provided by (Responsible Party):
NCT02180659
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals









Probuphine Graphic

 

 

 

Continuous Drug Delivery Technology

 

The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

 



Fanapt® (iloperidone)

 

Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.




Company Overview



Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.

 

Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


 

The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] www.otcbb.com) quotations system. For further information please contact info@titanpharm.com

 

Management Team

President
Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.

 



Board of Directors

 
 
  






 

Strategic Alliances


In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

 





Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at     sbhonsle@titanpharm.com

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TTNP
Current Price
Volume:
Bid Ask Day's Range
Wiki
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:13:05 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:08:51 PM
TTNP News: Statement of Ownership (sc 13g) 10/10/2014 10:20:57 AM
TTNP News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 10/03/2014 03:20:22 PM
TTNP News: Current Report Filing (8-k) 10/03/2014 09:52:33 AM
PostSubject
#3684  Sticky Note ****Addicts DESPERATELY Waiting For A Lifesaver**** TRUTH 09/27/14 11:41:37 AM
#3825   You're grasping at straws. matthewverymuch 10/30/14 10:12:27 AM
#3824   Maybe something or nothing, I always check out turks 10/29/14 10:46:08 PM
#3823   If they are over the 5% yes they turks 10/29/14 12:59:48 PM
#3822   It's more like 17-18 million dollars.. matthewverymuch 10/29/14 10:24:58 AM
#3821   Nothing else has been filed, so who knows? matthewverymuch 10/29/14 10:24:19 AM
#3820   Yahoo shows now outstanding shares at 110 turks 10/29/14 08:53:00 AM
#3819   Yeah..nothing since last cc, nearly 3 months ago. matthewverymuch 10/28/14 02:10:56 PM
#3818   Baffles me on EU. Think they would be bluejacket6 10/28/14 02:01:27 PM
#3817   Hoping to hear at least something positive to matthewverymuch 10/28/14 01:28:33 PM
#3816   Sunil resignation would be a start. bluejacket6 10/28/14 12:46:58 PM
#3815   What will cause us to rise out of matthewverymuch 10/28/14 10:03:48 AM
#3814   If certain "conditions" are met, of course. ;-) TRUTH 10/24/14 03:10:16 AM
#3813   Might very well be someday!! bluejacket6 10/23/14 04:37:58 PM
#3812   That's all I needed to see.... TRUTH 10/22/14 06:11:40 PM
#3811   Braeburn is responsible for chronic pain indication costs .. matthewverymuch 10/22/14 06:01:27 PM
#3810   Whatever gets the job done is fine with me TRUTH 10/22/14 05:28:33 PM
#3809   Whatever gets the job done is fine with matthewverymuch 10/22/14 01:03:09 PM
#3808   Something tells me that Braeburn will include all TRUTH 10/22/14 12:03:03 PM
#3807   Jama study on burprenorphine maintenance therapy vs tapering. http://archinte.ja matthewverymuch 10/22/14 10:18:26 AM
#3806   wasn't trying to challenge you. TRUTH 10/21/14 01:54:23 AM
#3805   I thought the market would react favorably to TRUTH 10/21/14 01:50:32 AM
#3804   Btw..wasn't trying to challenge you.may have come off matthewverymuch 10/21/14 01:30:21 AM
#3803   I thought the market would react favorably to matthewverymuch 10/21/14 01:27:29 AM
#3802   You really think the market will react favorably TRUTH 10/21/14 12:25:15 AM
#3801   You really think the market will react favorably matthewverymuch 10/20/14 11:42:33 PM
#3800   I used the market as a reference because TRUTH 10/20/14 06:23:49 PM
#3799   Did the market care about titan's pd track matthewverymuch 10/20/14 06:01:49 PM
#3798   I won't speak for Titan but it would TRUTH 10/20/14 05:33:43 PM
#3797   Are you saying that titan is late to matthewverymuch 10/20/14 02:22:50 PM
#3796   Genervon Announces ALS and PD Phase 2a Trial Results TRUTH 10/20/14 08:42:54 AM
#3793   However, the abuse potential for taking the whole Rentier 10/18/14 09:51:24 AM
#3792   When swallowed intact, however, Embeda can still be Rentier 10/18/14 09:34:29 AM
#3791   Two Drug Firms Fighting Opioid Abuse TRUTH 10/18/14 02:48:12 AM
#3790   Annual Symposium Today On Opioid Drug Abuse TRUTH 10/18/14 02:32:50 AM
#3789   FDA approves labeling with abuse-deterrent features for third TRUTH 10/18/14 02:11:09 AM
#3788   Finra lifts halt on OTC equity securities, will TRUTH 10/17/14 01:24:23 PM
#3787   Ut oh, looks like the afternoon muppet dump Rentier 10/17/14 12:20:21 PM
#3786   I am long in the market, too.no big matthewverymuch 10/15/14 01:02:07 PM
#3785   Be lucky you not long in market they Rentier 10/15/14 12:48:57 PM
#3784   Not much of a rise from this news...people matthewverymuch 10/15/14 12:42:16 PM
#3783   Yes been there since Spheramine days, lied to Rentier 10/15/14 10:30:38 AM
#3782   Rubin has been there much longer, right? matthewverymuch 10/15/14 10:28:57 AM
#3781   Looks like now Sunil has total of 356.5k Rentier 10/15/14 10:26:00 AM
#3780   The addiction recovery space is big business...chronic pain matthewverymuch 10/15/14 10:20:49 AM
#3779   Who knows what his time horizon is for matthewverymuch 10/15/14 10:13:35 AM
#3778   More than that now...probably closer to $200k. Rentier 10/15/14 10:09:55 AM
#3777   not on the wild west OTC. TRUTH 10/15/14 10:01:28 AM
#3776   Sunil bought about 4.5x more matthewverymuch 10/15/14 09:48:47 AM
#3775   Should revisit DD if you think the future bluejacket6 10/15/14 09:48:16 AM
#3774   It is on a major down trend and maxxm 10/15/14 09:46:02 AM
PostSubject